ID HAC8_HALAS Reviewed; 283 AA.
AC P83716; Q6JSL9;
DT 16-FEB-2004, integrated into UniProtKB/Swiss-Prot.
DT 14-MAY-2014, sequence version 2.
DT 13-SEP-2023, entry version 34.
DE RecName: Full=Pre-protein-C8;
DE Contains:
DE RecName: Full=Immunity protein HalI;
DE Contains:
DE RecName: Full=Halocin-C8;
DE Short=HalC8;
DE Flags: Precursor;
GN Name=proC8;
OS Halobacterium sp. (strain AS7092).
OC Archaea; Euryarchaeota; Stenosarchaea group; Halobacteria; Halobacteriales;
OC Halobacteriaceae; Halobacterium.
OX NCBI_TaxID=245739;
RN [1]
RP NUCLEOTIDE SEQUENCE [GENOMIC DNA], MASS SPECTROMETRY, INDUCTION, AND
RP PROTEOLYTIC PROCESSING.
RC STRAIN=AS7092;
RX PubMed=15978083; DOI=10.1111/j.1365-2958.2005.04705.x;
RA Sun C., Li Y., Mei S., Lu Q., Zhou L., Xiang H.;
RT "A single gene directs both production and immunity of halocin C8 in a
RT haloarchaeal strain AS7092.";
RL Mol. Microbiol. 57:537-549(2005).
RN [2]
RP PROTEIN SEQUENCE OF 208-222, AND SUBCELLULAR LOCATION.
RC STRAIN=AS7092;
RX PubMed=12811620; DOI=10.1007/s00792-003-0335-6;
RA Li Y., Xiang H., Liu J., Zhou M., Tan H.;
RT "Purification and biological characterization of halocin C8, a novel
RT peptide antibiotic from Halobacterium strain AS7092.";
RL Extremophiles 7:401-407(2003).
RN [3]
RP SUBUNIT, AND MUTAGENESIS OF ALA-61; ARG-62; GLU-63; LEU-64; ALA-65; LYS-66;
RP THR-67; PRO-68; ALA-69; PHE-70; ARG-71; GLU-72; LEU-73; ALA-74 AND GLN-75.
RC STRAIN=AS7092;
RX PubMed=18658263; DOI=10.1128/jb.00665-08;
RA Mei S., Sun C., Liu X., Lu Q., Cai L., Li Y., Xiang H.;
RT "The helix-loop-helix motif at the N terminus of HalI is essential for its
RT immunity function against halocin C8.";
RL J. Bacteriol. 190:6501-6508(2008).
CC -!- FUNCTION: [Halocin-C8]: Has antibacterial activity against a wide
CC variety of haloarchaeons. Causes cell lysis and death, possibly by
CC disrupting the cell wall (PubMed:12811620).
CC {ECO:0000269|PubMed:12811620}.
CC -!- FUNCTION: [Immunity protein HalI]: Acts as an immunity protein for
CC halocin-C8. Able to block the halocin-C8 activity by sequestering the
CC activity of halocin-C8 through specific and direct binding
CC (PubMed:15978083, PubMed:18658263). {ECO:0000269|PubMed:15978083,
CC ECO:0000269|PubMed:18658263}.
CC -!- SUBUNIT: Immunity protein HalI interacts with Halocin-C8; the
CC interaction is direct. {ECO:0000269|PubMed:18658263}.
CC -!- SUBCELLULAR LOCATION: [Halocin-C8]: Secreted. Note=Secreted
CC (PubMed:15978083, PubMed:12811620). {ECO:0000269|PubMed:12811620,
CC ECO:0000269|PubMed:15978083}.
CC -!- SUBCELLULAR LOCATION: [Immunity protein HalI]: Cell membrane.
CC Note=Exclusively localizes to the cell membrane.
CC {ECO:0000269|PubMed:15978083}.
CC -!- INDUCTION: Increases to maximal levels upon transition from exponential
CC to stationary phase. {ECO:0000269|PubMed:15978083}.
CC -!- DOMAIN: The helix-loop-helix (HLH) region is essential for immunity
CC function of Immunity protein HalI and interaction with Halocin-C8.
CC {ECO:0000269|PubMed:18658263}.
CC -!- PTM: Predicted to be exported by the Tat system. The position of the
CC signal peptide cleavage has not been experimentally proven.
CC {ECO:0000255|PROSITE-ProRule:PRU00648, ECO:0000269|PubMed:15978083}.
CC -!- MASS SPECTROMETRY: [Halocin-C8]: Mass=7427.1; Method=MALDI;
CC Evidence={ECO:0000269|PubMed:15978083};
CC -!- MISCELLANEOUS: [Halocin-C8]: Is quite robust, as it can be desalted,
CC boiled, subjected to organic solvents, and stored at 4 degrees Celsius
CC for extended periods without losing activity.
CC {ECO:0000305|PubMed:12811620}.
CC ---------------------------------------------------------------------------
CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC ---------------------------------------------------------------------------
DR EMBL; DQ137141; AAQ82548.1; -; Genomic_DNA.
DR AlphaFoldDB; P83716; -.
DR TCDB; 9.A.45.1.1; the archaeocin/halocin c8 (halc8) family.
DR GO; GO:0005576; C:extracellular region; IDA:UniProtKB.
DR GO; GO:0005886; C:plasma membrane; IEA:UniProtKB-SubCell.
DR GO; GO:0042742; P:defense response to bacterium; IDA:UniProtKB.
DR GO; GO:0031640; P:killing of cells of another organism; IEA:UniProtKB-KW.
DR InterPro; IPR031033; Halocin_C8_dom.
DR InterPro; IPR006311; TAT_signal.
DR NCBIfam; TIGR04449; halocin_C8_dom; 1.
DR PROSITE; PS51318; TAT; 1.
PE 1: Evidence at protein level;
KW Antibiotic; Antimicrobial; Bacteriocin; Cell membrane;
KW Direct protein sequencing; Membrane; Secreted; Signal.
FT SIGNAL 1..40
FT /note="Tat-type signal"
FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00648"
FT CHAIN 41..207
FT /note="Immunity protein HalI"
FT /id="PRO_0000429048"
FT CHAIN 208..283
FT /note="Halocin-C8"
FT /id="PRO_0000195165"
FT REGION 61..75
FT /note="Helix-loop-helix (HLH) region"
FT MUTAGEN 61
FT /note="A->D: No effect on immunity function of Immunity
FT protein HalI and interaction with Halocin-C8."
FT /evidence="ECO:0000269|PubMed:18658263"
FT MUTAGEN 62
FT /note="R->A: Slightly decreased immunity function of
FT Immunity protein HalI and interaction with Halocin-C8."
FT /evidence="ECO:0000269|PubMed:18658263"
FT MUTAGEN 63
FT /note="E->A: Slightly decreased immunity function of
FT Immunity protein HalI and interaction with Halocin-C8."
FT /evidence="ECO:0000269|PubMed:18658263"
FT MUTAGEN 64
FT /note="L->A: Impaired immunity function of Immunity protein
FT HalI and interaction with Halocin-C8."
FT /evidence="ECO:0000269|PubMed:18658263"
FT MUTAGEN 65
FT /note="A->P: No effect on immunity function of Immunity
FT protein HalI and interaction with Halocin-C8."
FT /evidence="ECO:0000269|PubMed:18658263"
FT MUTAGEN 66
FT /note="K->P: No effect on immunity function of Immunity
FT protein HalI and interaction with Halocin-C8."
FT /evidence="ECO:0000269|PubMed:18658263"
FT MUTAGEN 67
FT /note="T->A: No effect on immunity function of Immunity
FT protein HalI and interaction with Halocin-C8."
FT /evidence="ECO:0000269|PubMed:18658263"
FT MUTAGEN 68
FT /note="P->A: No effect on immunity function of Immunity
FT protein HalI and interaction with Halocin-C8."
FT /evidence="ECO:0000269|PubMed:18658263"
FT MUTAGEN 69
FT /note="A->V: No effect on immunity function of Immunity
FT protein HalI and interaction with Halocin-C8."
FT /evidence="ECO:0000269|PubMed:18658263"
FT MUTAGEN 70
FT /note="F->A: No effect on immunity function of Immunity
FT protein HalI and interaction with Halocin-C8."
FT /evidence="ECO:0000269|PubMed:18658263"
FT MUTAGEN 71
FT /note="R->A: No effect on immunity function of Immunity
FT protein HalI and interaction with Halocin-C8."
FT /evidence="ECO:0000269|PubMed:18658263"
FT MUTAGEN 72
FT /note="E->A: No effect on immunity function of Immunity
FT protein HalI and interaction with Halocin-C8."
FT /evidence="ECO:0000269|PubMed:18658263"
FT MUTAGEN 73
FT /note="L->A: Impaired immunity function of Immunity protein
FT HalI and interaction with Halocin-C8."
FT /evidence="ECO:0000269|PubMed:18658263"
FT MUTAGEN 74
FT /note="A->V: No effect on immunity function of Immunity
FT protein HalI and interaction with Halocin-C8."
FT /evidence="ECO:0000269|PubMed:18658263"
FT MUTAGEN 75
FT /note="Q->A: No effect on immunity function of Immunity
FT protein HalI and interaction with Halocin-C8."
FT /evidence="ECO:0000269|PubMed:18658263"
SQ SEQUENCE 283 AA; 29379 MW; FF5B95B523D29A12 CRC64;
MKEDNNTSEE SGRINRRNVL KTVGAAGLFA AGSTGMAAAA DSLSQAEEPK LLTGTEKRTL
ARELAKTPAF RELAQRARAD GAQIRSDADS IVAGYARGED FAREVVQYDL ENLTDAAEAS
IVIGRNPETG EIEVANLDYY YETDDGVLDE VHRFEPTNAS ETDGVQSAAT SDGATVIAVD
TDAIREAQNS EIDVDESSPS NAAPTPADID ITGCSACKYA AGQVCTIGCS AAGGFICGLL
GITIPVAGLS CLGFVEIVCT VADEYSGCGD AVAKEACNRA GLC
//
